Close X
Attorney Spotlight

What emerging trend in shareholder litigation does Britt Latham find most interesting in his practice today?    Find out more>

Search

Close X

Experience

Search our Experience

Experience Spotlight

Envision to Sell to KKR for $9.9 Billion

We represented Envision Healthcare Corporation (NYSE: EVHC) in its definitive agreement to sell to KKR in an all-cash transaction for $9.9 billion, including debt. KKR will pay $46 per Envision share in cash to buy the company, marking a 32 percent premium to the company's volume-weighted average share price from November 1, when Envision announced it was considering its options. The transaction is expected to close the fourth quarter of 2018. Read more


Envision Healthcare

Close X

Thought Leadership

Enter your search terms in the relevant box(es) below to search for specific Thought Leadership.
To see a recent listing of Thought Leadership, click the blue Search button below.

Thought Leadership Spotlight

Six Things to Know Before Buying a Physician Practice spotlight

Dermatology, ophthalmology, radiology, urology…the list goes on. Yet, in any physician practice management transaction, there are six key considerations that apply and, if not carefully managed, can derail a transaction. Download the 6 Things to Know Before Buying a Physician Practice to keep your physician practice management transactions on track.

Click here to download the guide.

John C. Eason

Associate

Nashville
(615) 742-7830 TEL
(615) 742-2772 FAX

John C. Eason

Associate

Nashville
(615) 742-7830 TEL
(615) 742-2772 FAX
Nashville
(615) 742-7830 TEL
(615) 742-2772 FAX

John Eason focuses his practice on representing clients in government enforcement actions, investigations, and related litigation, particularly involving the False Claims Act (FCA). John has represented companies and individuals, particularly in the healthcare industry, in responding to inquiries and investigations by the Department of Justice, U.S. Attorneys' Offices, Office of the Inspector General of the Department of Health and Human Services, and other federal and state agencies, regarding healthcare and procurement fraud issues. John also has experience defending clients against lawsuits brought under the Federal False Claims Act, state false claims acts, and other fraud statutes, as well as the FCA's anti-retaliation provision. John has assisted corporate clients with internal compliance assessments and internal investigations regarding regulatory and compliance issues. John is a contributor to and editor of the firm's annual Healthcare Fraud Year in Review and the firm's Inside the FCA Blog.

Prior to joining Bass, Berry & Sims, John served a one-year clerkship with the Honorable Anita B. Brody on the U.S. District Court for the Eastern District of Pennsylvania. John earned his law degree from Vanderbilt University Law School where he served as articles editor for the Vanderbilt Law Review and as a member of the managing council of the Moot Court Board. While in law school, he interned with the Honorable John S. Bryant, Magistrate Judge for the U.S. District Court for the Middle District of Tennessee.

Memberships

American Health Lawyers Association (AHLA)

Tennessee Bar Association

News

View More

Representative Experience

View More

Publications

View More

Media Mentions

View More

Accolades

Vanderbilt Law Review — Articles Editor

Moot Court Board — Managing Council

Law Clerk to Hon. Anita B. Brody, U.S. District Court for the Eastern District of Pennsylvania (2011-2012)

Notice

Visiting, or interacting with, this website does not constitute an attorney-client relationship. Although we are always interested in hearing from visitors to our website, we cannot accept representation on a new matter from either existing clients or new clients until we know that we do not have a conflict of interest that would prevent us from doing so. Therefore, please do not send us any information about any new matter that may involve a potential legal representation until we have confirmed that a conflict of interest does not exist and we have expressly agreed in writing to the representation. Until there is such an agreement, we will not be deemed to have given you any advice, any information you send may not be deemed privileged and confidential, and we may be able to represent adverse parties.